Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK.

IF 3.7 3区医学 Q2 ALLERGY

Journal of Asthma and Allergy Pub Date : 2025-02-06 eCollection Date: 2025-01-01 DOI:10.2147/JAA.S452747

Imène Gouia, Florence Joulain, Yi Zhang, Christopher Ll Morgan, Asif H Khan

{"title":"Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK.","authors":"Imène Gouia, Florence Joulain, Yi Zhang, Christopher Ll Morgan, Asif H Khan","doi":"10.2147/JAA.S452747","DOIUrl":null,"url":null,"abstract":"Background: UK pediatric asthma prevalence is among the highest in Europe, and although the clinical and economic burden of asthma in UK adults is well described, childhood asthma data is lacking. We assessed the clinical and economic burden of asthma in children in the UK to better understand the impact of pediatric asthma.Methods: This was a retrospective, case-matched, longitudinal analysis using the Clinical Practice Research Datalink GOLD database and linked patient-level data (Hospital Episode Statistics and Office for National Statistics datasets) of selected patient (aged 6-11 years) records in 2017. Severe exacerbation and re-exacerbation rates per patient-year (PPY), all-cause healthcare resource utilization (HCRU), and HCRU-related costs were assessed in asthma patients versus matched non-asthma controls, stratified by severity.Results: Among 5950 patients, severe exacerbation rate was 0.06, 0.17 and 0.31 PPY for mild, moderate, and severe asthma, respectively. Incident rate of severe exacerbations were higher for moderate asthma (incident rate ratios [IRR; 95% CI] 2.87 [2.30-3.56], P<0.0001) and severe asthma (5.19 [4.20-6.41], P<0.0001) versus mild asthma. Risk of re-exacerbation was significantly increased for severe versus mild asthma (hazard ratio [95% CI]: 2.98 [1.90-4.65], P<0.001). All-cause HCRU (IRR [95% CI]) was higher in severe asthma patients versus controls (primary care: 3.81 [3.54-4.09], P<0.0001; inpatient admissions: 3.23 [2.31-4.62], P<0.0001]); total-cost ratios relative to controls for mild, moderate, and severe asthma were 1.58 (1.39-1.78, P<0.0001), 2.56 (1.97-3.33, P<0.0001), and 3.42 (2.54-4.61, P<0.0001), respectively. Asthma-related costs increased with severity (total-cost ratios: moderate versus mild, 1.68 [1.45-1.97], P<0.0001; severe versus mild, 2.67 [2.21-3.25], P<0.0001).Conclusion: In children with asthma in the UK, increasing disease severity was associated with increased risk of severe exacerbations, re-exacerbations, and increased HCRU and costs.","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"161-171"},"PeriodicalIF":3.7000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809225/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma and Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JAA.S452747","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: UK pediatric asthma prevalence is among the highest in Europe, and although the clinical and economic burden of asthma in UK adults is well described, childhood asthma data is lacking. We assessed the clinical and economic burden of asthma in children in the UK to better understand the impact of pediatric asthma.

Methods: This was a retrospective, case-matched, longitudinal analysis using the Clinical Practice Research Datalink GOLD database and linked patient-level data (Hospital Episode Statistics and Office for National Statistics datasets) of selected patient (aged 6-11 years) records in 2017. Severe exacerbation and re-exacerbation rates per patient-year (PPY), all-cause healthcare resource utilization (HCRU), and HCRU-related costs were assessed in asthma patients versus matched non-asthma controls, stratified by severity.

Results: Among 5950 patients, severe exacerbation rate was 0.06, 0.17 and 0.31 PPY for mild, moderate, and severe asthma, respectively. Incident rate of severe exacerbations were higher for moderate asthma (incident rate ratios [IRR; 95% CI] 2.87 [2.30-3.56], P<0.0001) and severe asthma (5.19 [4.20-6.41], P<0.0001) versus mild asthma. Risk of re-exacerbation was significantly increased for severe versus mild asthma (hazard ratio [95% CI]: 2.98 [1.90-4.65], P<0.001). All-cause HCRU (IRR [95% CI]) was higher in severe asthma patients versus controls (primary care: 3.81 [3.54-4.09], P<0.0001; inpatient admissions: 3.23 [2.31-4.62], P<0.0001]); total-cost ratios relative to controls for mild, moderate, and severe asthma were 1.58 (1.39-1.78, P<0.0001), 2.56 (1.97-3.33, P<0.0001), and 3.42 (2.54-4.61, P<0.0001), respectively. Asthma-related costs increased with severity (total-cost ratios: moderate versus mild, 1.68 [1.45-1.97], P<0.0001; severe versus mild, 2.67 [2.21-3.25], P<0.0001).

Conclusion: In children with asthma in the UK, increasing disease severity was associated with increased risk of severe exacerbations, re-exacerbations, and increased HCRU and costs.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Asthma and Allergy Medicine-Immunology and Allergy

CiteScore

5.30

自引率

6.20%

发文量

185

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.